RESISTANCE OF S. PNEUMONIAE TO ANTIMICROBIAL AGENTS IN ADULTS WITH NOSOCOMIAL PNEUMONIA IN KAZAN BEFORE AND DURING THE COVID-19 PANDEMIC



如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective - To study trends in the frequency of isolation of pneumococcal strains resistant to antimicrobial drugs in adult patients with community-acquired pneumonia in Kazan in 2019-2022.

Methods. A descriptive study of pneumococcal resistance to antibiotics was conducted using material collected at the Laboratory Diagnostic Center of the SAHI «RCIDH». Sputum from adult patients with community-acquired pneumonia received from 11 medical organizations of the city in the period from 2019 to 2022 was examined. Antibiotic resistance was determined by the disk diffusion method and interpreted according to the requirements of the russian guidelines "Determination of the susceptibility of microorganisms to antimicrobial drugs". The frequency of isolation of resistant pneumococcal strains and changes in antibiotic resistance profiles were assessed. A retrospective analysis of bacterial pneumonia incidence in Kazan was conducted for the period 2019-2024.

Results. For the period 2019-2024, the incidence of bacterial community-acquired pneumonia among the adult population of Kazan increased from 76.8 0/0000 (95% CI: 71.3-82.3) in 2019 to 88.3 0/0000 in 2024 (95% CI: 82.4-94.2) (p=0.002). The highest incidence rate was noted in 2024, the minimum in 2021. In general, of all 196 S. pneumoniae isolates studied, the proportion of strains non-susceptible to penicillin was 38.3% (95% CI 31.5-45.1), to erythromycin - 26.0% (95% CI 19.8-32.2), to levofloxacin - 10.7% (95% CI 6.1-15.3), to clindamycin - 16.8% (95% CI 11.5-22.1), to tetracycline - 22.3% (95% CI 14.1-28.5), to co-trimoxazole - 30.8% (95% CI 24.3-37.3).

Conclusion. A high frequency of isolation of pneumococci resistant to the main classes of antibacterial drugs was noted. During the peak of the COVID-19 pandemic (2020-2022), no changes were observed in the frequency of isolation of antibiotic-resistant pneumococcal strains in patients with community-acquired bacterial pneumonia and no changes in their antibiotic resistance profile compared to 2019.

全文:

受限制的访问

作者简介

Sergej Semenov

Kazan State Medical University

编辑信件的主要联系方式.
Email: sergejsemenov596@gmail.com
ORCID iD: 0000-0003-3437-832X
俄罗斯联邦

Gulshat Khasanova

Казанский государственный медицинский университет

Email: gulshatra@mail.ru
ORCID iD: 0000-0002-1733-2576
SPIN 代码: 6704-2840
俄罗斯联邦

Elena Yumagulova

Email: Elena.Yumagulova@tatar.ru
ORCID iD: 0000-0003-4012-2371

Marina Belova

Email: marina116bp@yandex.ru
ORCID iD: 0000-0001-9579-3370

参考

  1. The World Health Organization. Pneumococcal infection: surveillance standards for controlled infections. Pneumococcal infection. Published on September 4, 2018. Access mode: https://www.who.int/ru/publications/m/item/vaccine-preventable-diseases-surveillance-standards-pneumococcus. Date of request: 29.01.2024.
  2. Mazur L. I., Pyrkova S. A., Kurshina M. V., Bekeeva I. Y. Assessment of the safety and effect of the pneumococcal vaccine "Preventar-13" on the incidence of pneumonia and otitis media in children of the first five years of life. Pulse Medical and Pharmaceutical journal.2024. 26(10): 58-65. doi: 10.26787/nydha-2686-6838-2024-26-10-58-65
  3. Avdeeva M. G., Shubina G. V., Ganzha A. A., Zhuravleva E. V. Community-acquired pneumonia in infectious hospital patients: problems of antimicrobial drug resistance development. Epidemiology and infectious diseases. 2018. 23(3):108-113.doi: 10.18821/1560-9529-2018-23-3-108-113
  4. COVID-19 & Antimicrobial Resistance. Access mode: https://www.cdc.gov/antimicrobial-resistance/data-research/threats/COVID-19.html .Date of request: 29.01.2024.
  5. Stavar-Matei L., Mihailov O.M., Nechita A., et al. Impact of COVID-19 on Pneumococcal Acute Otitis Media, Antibiotic Resistance, and Vaccination in Children. Infect Drug Resist. 2024;17:5567-5578. doi: 10.2147/IDR.S496057
  6. Almeida S.C.G., Lemos A.P.S., Bierrenbach A.L., et al. Serotype Distribution and Antimicrobial Susceptibility Pattern of Streptococcus pneumoniae in COVID-19 Pandemic Era in Brazil. Microorganisms. 2024;12(2):401. doi: 10.3390/microorganisms12020401
  7. Sempere J., Llamosí M., López Ruiz B., et al. Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study. Lancet Microbe. 2022;3(10):e744-e752. doi: 10.1016/S2666-5247(22)00127-6
  8. Manzanal A., Vicente D., Alonso M., et al.Impact of the progressive uptake of pneumococcal conjugate vaccines on the epidemiology and antimicrobial resistance of invasive pneumococcal disease in Gipuzkoa, northern Spain, 1998-2022. Front Public Health. 2023;11:1238502. doi: 10.3389/fpubh.2023.1238502
  9. CDC’s 2019 Antibiotic Resistance Threats Report. Access mode: www.cdc.gov/DrugResistance/Biggest-Threats.html .Date of request: 29.01.2024.
  10. Hjalmarsdottir M.A., Haraldsson G., Quirk S.J., et al. Reduction of antimicrobial resistant pneumococci seven years after introduction of pneumococcal vaccine in Iceland. PLoS One. 2020;15(3):e0230332. doi: 10.1371/journal.pone.0230332
  11. Kaur R., Pham M., Yu K.O.A., Pichichero M.E. Rising Pneumococcal Antibiotic Resistance in the Post-13-Valent Pneumococcal Conjugate Vaccine Era in Pediatric Isolates From a Primary Care Setting. Clin Infect Dis. 2021;72(5):797-805. doi: 10.1093/cid/ciaa157
  12. Order of the Ministry of Health of the Russian Federation dated March 21, 2014 No. 125n «On approval of the national calendar of preventive vaccinations and the calendar of preventive vaccinations for epidemic indications».
  13. MAKMAC. Russian recommendations. Determination of the sensitivity of microorganisms to antimicrobial drugs. Version 2024-02. Smolensk, 2024.
  14. Savilov E.D., Astafyev V.A., Zhdanov S.N., Zarudnev E.A. Methods of statistical processing of the material. Novosibirsk: Science Center, 2011.
  15. Agresti A., Coull B. Approximate is better than exact for interval estimation of binomial proportions. Americanstatistician.1998; 52: 119—126.
  16. Khasanova G.R., Semenov S.A. The impact of the COVID-19 pandemic on the manifestations of the epi-demic process of community-acquired pneumonia. Medical almanac.2025;1(1):198-204. doi:
  17. On the state of sanitary and epidemiological welfare of the population in the Republic of Tatarstan in 2023: State Report. K.: Department of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare in the Republic of Tatarstan (Tatarstan), 2024.
  18. On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2023: State Report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Welfare, 2024.
  19. Interim guidelines "Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19)", Version 9, 2020. Версия 9, 2020. https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf .
  20. Kuzmenkov A.Yu., Vinogradova A.G., Trushin I.V., Eidelstein M.V., Avramenko A.A., Dehnich A.V., Kozlov R.S. AMRmap is an antibiotic resistance monitoring system in Russia. Clinical microbiology and antimicrobial chemotherapy. 2021;23(2): 198-204. doi: 10.36488/cmac.2021.2.198-204
  21. Li L., Ma J., Yu Z., Zhang W., Sun H. Epidemiological characteristics and antibiotic resistance mechanisms of Streptococcus pneumoniae: an updated review. Microbiological Research 2023 Jan; 266:127221. doi: 10.1016/j.micres.2022.127221

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-vector,


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80652 от 15.03.2021 . Учредитель ООО "Эко-Вектор Ай-Пи" (ОГРН 1157847215338).